×

RNS Number : 8402G

ValiRx PLC

30 November 2020

 

30 November 2020

("ValiRx", the "Company" or the "Group")

 

VAL201 Clinical Trial Full Data Results

 

Full dataset confirms VAL201 is a safe and well-tolerated drug candidate

 

Company to host webcast for investors on 8 December 2020 at 2 pm GMT

 

London, UK – ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, is pleased to report that it has received the full dataset to be used for the Clinical Study Report from the Phase 1/2 clinical trial of its lead asset, VAL201, for the treatment of locally advanced or metastatic prostate cancer and performed at University College Hospital (UCLH), London. This expands the positive headline results announced on 28 September 2020.

 

The dataset provides a complete breakdown of the full data of safety and tolerability as well as evidence for encouraging disease impact as observed during the clinical trial.  This data will be used to formulate the Clinical Study Report and to report the results on the www.clinicaltrials.gov database.  Additional detailed analysis of the results will form the basis of peer-reviewed journal publications.

 

The full dataset is available to download on the Company website, https://www.valirx.com/our-pipeline/val201 .

 

Key details of the findings:

 

Recruitment Criteria

· Twelve patients were recruited according to the criteria of having incurable, locally advanced or metastatic prostate cancer with rising PSA[1] (Prostate-Specific Antigen) on three consecutive samples and absent or very mild prostate cancer-related symptoms.

· The demographics and a detailed breakdown of the patients recruited is provided in the download.

 

Disease Impact

· The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria.  The dataset now received provides the detailed breakdown of this by providing both the PSA modulation afforded by the treatment, and the tumour response.

· The PSA data, a recognised surrogate of disease progression, shows two patients seeing a decrease in PSA during their treatment period, one of which maintained the decrease throughout the trial. An analysis of the doubling time of patients shows a statistically significant (p<0.05, two-tailed Wilcoxon Signed-Rank test for paired samples) increase in PSA doubling time comparing pre-treatment doubling time to post-treatment doubling time.  The PSA doubling time would be expected to be unchanged if the treatment was having no impact, so an increase in doubling time demonstrates a slowing rate of growth of PSA levels.

· The tumour response data demonstrates that patients did not have an increase in metastatic lesions during the treatment period, and that metastatic lesions already present did not grow at all in two out of three patients, suggesting a positive influence of VAL201 on the disease.

 

Safety and Tolerability

The further breakdown of the safety data confirms the well tolerated nature of the drug.

 

Additionally, the initial pharmacokinetic analysis supports the safety profile in confirming the drug is processed and cleared from the body in the manner expected.

 

The Company expects to publish the data on the National Institute of Health's (NIH) public database ClinicalTrials.gov, as well as produce research papers for peer-reviewed publications.

 

Investor Webcast

ValiRx will host a webcast for investors on Tuesday, 8 December 2020 at 2pm GMT to discuss the findings of the study.

 

· Prior to the webcast, questions can be submitted online to [email protected]

· During the webcast, questions can be submitted through the webcast link below.

 

To participate, please click on the link below at the designated time:

 

https://webcasting.brrmedia.co.uk/broadcast/5fc12476b19325729a9d841f

The webcast will be available on demand following a link on the Company's website after the broadcast.  This webcast replaces the usual monthly Q&A publication, and a written summary of questions with answers will be provided after the event.

 

Dr Suzy Dilly, Chief Executive Officer commented: "This data demonstrates the potential of VAL201 for further development towards a treatment for patients with prostate cancer.  Providing the data breakdown to support and explain the headline numbers is a crucial step and allows us to delve further into analysis of the results. The highly encouraging 54.5% response rate remains unchanged and being able to interrogate the data in more detail allows us to explore the possibilities for optimising the treatment through future trial with partners.

 

"We continue to share the dataset with potential industry partners who expressed an interest after the headline results were released in September 2020, and I look forward to the discussions that I am confident will arise as we evaluate all options for further clinical development.  We would like to thank the team for their hard work and our shareholders for their support."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

 

Ends

 

For further information please contact:

 

ValiRx plc	Tel: +44 (0) 2476 796496 www.valirx.com
Suzanne Dilly, CEO	[email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: +44 (0) 20 7469 0930
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: +44 (0) 20 8148 3040 [email protected]

 

 

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

 

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

 

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

 

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

 

About VAL201

VAL201 is a short peptide being studied as a potential treatment for prostate cancer. The peptide structure is inspired by the naturally occurring androgen receptor and is designed to intercept and prevent the binding of the androgen receptor to SRC kinase – an enzyme implicated in cancerous cell growth pathways. By preventing the androgen-mediated activation of SRC kinase, VAL201 can potentially prevent cancerous cell proliferation (or growth) without interfering with other functions of either the androgen receptor or SRC kinase. This precision method, mimicking a natural process, proposes a high specificity of cancer treatment with a lower side effect profile. VAL201 was licensed from CRT (part of CRUK) in 2010 and developed through preclinical development into this clinical trial in patients with advanced prostate cancer. The study was held at University College Hospital (UCLH), London.

 

About the VAL201-001 clinical trial

The clinical trial: "A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours" opened to recruitment in December 2014 and closed in January 2020.

 

Patients were scheduled for treatment of a once weekly injection of VAL201 in 3 week cycles for a maximum of 6 cycles.  A total of 12 patients received at least 1 dose of VAL201.

 

Patients were eligible if they were: Adult men (over the age of 18) with incurable locally advanced or metastatic prostate cancer who had relapsed following radiotherapy treatment, are in 'watchful waiting' or where a policy of intermittent hormone therapy had been decided.  Patients were expected to have no or only mild symptoms relating to their prostate cancer. (ClinicalTrials.gov identifier: NCT02280317)

 

About Prostate Cancer

Around 48,500 men are diagnosed with prostate cancer in the UK each year[2]. In men, it is the most common cancer in the UK.  Prostate cancer is most common in older men. On average each year 35 out of 100 (35%) of new cases are in men aged 75 and over.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

 

Factors that could cause actual results to differ materially from those in the forward-looking statements include risks relating to unanticipated costs, liabilities or delays; failure or delays in research and development programs; the safety and efficacy of the Company's product candidates and the likelihood of clinical data to be positive and of such product candidates to be approved by the applicable regulatory authorities; unanticipated changes relating to competitive factors in the Company's industry; risks relating to the Company's capitalisation, resources and ownership structure, the availability of sufficient resources for company operations and to conduct or continue planned clinical development programs; the outcome of any legal proceedings; risks related to the ability to correctly estimate operating expenses; risks related to the ability to project future cash utilisation and reserves needed for contingent future liabilities and business operations; risks related to the changes in market prices of the Company's ordinary shares; the Company's ability to hire and retain key personnel; changes in law or regulations affecting the Company; international, national or local economic, social or political conditions that could adversely affect the Company and its business; conditions in the credit markets; risks associated with assumptions the Company makes in connection with its critical accounting estimates and other judgments.

 

 

 

---

[1]The PSA test is a blood test used primarily to screen for prostate cancer. The test measures the amount of prostate-specific antigen (PSA) in the blood. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate gland.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCEANFNASEEFFA

Close

×

RNS Number : 4927F

Crimson Tide PLC

17 November 2020

 

Crimson Tide Plc

Contract Wins

 

Crimson Tide Plc (TIDE) is pleased to announce contract wins approaching £0.5m which demonstrate the appeal of mpro5 across sectors and the growing traction of its Internet of Things (IoT) capabilities.

Cadent, providers of the UK gas network and employing over 4000 staff, have invested in mpro5 within two of their four UK regions for the purpose of re-instatement works across the 82,000 miles of gas pipeline they manage.

The mpro5 platform has been deeply integrated with Cadent's SAP installation, allowing for real-time scheduling of remedial works to its multi-disciplinary re-instatement teams. The real-time data provided by mpro5 is already being used to ensure compliance with Local Authority guidelines and the Company is hopeful of a wider roll-out across all regions, and additional departments in due course.

Incentive QAS, the contract cleaning arm of Incentive FM – employing some 800 staff across the UK, have invested in mpro5 for the purposes of IoT-driven cleaning compliance at London's Citypoint skyscraper.

Using mpro5's proprietary IoT platform, areas throughout Citypoint are reporting real-time occupancy and usage data, allowing for automated scheduling of cleaning services based on demand rather than a schedule, driving a significant and immediate return on investment for the client.

Barrie Whipp, Chairman, commented: "Cadent is a very prestigious contract win for the Company and we are delighted with the integration with SAP, which opens up further possibilities with this global software supplier. Our Internet of Things offering is quite exciting in the way that it automatically schedules jobs and tasks for mpro5 users to complete. We are very pleased that Incentive has taken its first steps with the platform and we have other pilots in train for IoT which give us optimism for its wider adoption."

 

For further information:

 

Crimson Tide plc

Barrie Whipp / Luke Jeffrey   01892 542 444

 

finnCap (Nominated Adviser and Broker)

Corporate Finance: Julian Blunt / James Thompson  +44 20 7220 0500

Corporate Broking: Andrew Burdis +44 20 7220 0500

 

Alma PR (Financial PR)

Josh Royston +44 7780 901979

 

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAEAXFKFAXEFFA

Close

×

RNS Number : 3454F

Deepverge PLC

16 November 2020

 

16 November 2020

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

Update on detection of COVID-19 products

 

First deployments of Microtox PD in Ireland

 

License of patented breathalyser for Microtox BT COVID-19 breath test and initiation of Phase 3 field trials

 

 

DeepVerge has commenced deployment of near-source wastewater contamination test equipment ("Microtox PD") into water treatment plants in Ireland, with first shipments to China and the US expected by year-end.

 

Microtox PD units, retrofitted with AI based optofluidic pathogen identification scanners, are also being shipped to the University of Aberdeen CAT3 laboratory, adding to the ongoing trials with the live SARS-CoV-2, supplied by Public Health England.

 

In addition, DeepVerge has agreed to license a patented breathalyser from PulMoBioMed Limited ("PBM"), a spin-out technology company of Northumbria University, to capture SARS-CoV-2 particles in breath condensate for the DeepVerge optofluidic breath test ("Microtox BT").

 

Phase 3 field trials are expected to begin shortly at multiple sites in Northern England.  In collaboration with EcoWaterOS consortia partners, aggregated anonymised data will provide datasets for AI model simulations from human volunteers who will undergo COVID-19 testing with a combination of Microtox BT, a lateral flow antigen test and a rt-PCR test.  Sufficient datasets are anticipated to be complete early in 2021.

 

Gerard Brandon, CEO of DeepVerge, Commented:

"Phase 3 field trial testing is the last step to establish permanent anonymised mass surveillance of dangerous pathogens in wastewater, in real-time.  The field trials will combine the deployment of Microtox PD wastewater units and daily testing of individual volunteers with a Microtox BT breathalyser test, a lateral flow test and a PCR test.  The data from these tests are expected to simultaneously identify the source of COVID-19 cases, identify COVID-19 clusters, and indicate the size of each cluster in real-time. As the data grows, AI will offer the potential to predict the trajectory of growth of future clusters of Sars-CoV-2 or any future dangerous pathogen.  As we progress towards commercialisation, PulMoBioMed's patented technology will enable a quick roll-out of our Microtox BT breath test once field trials have completed.  We look forward to reporting the results in due course."

 

Dr Sterghios Moschos, MD of PulMoBioMed, added:

"We are delighted to be working with the team at DeepVerge and adding our PBM-Hale device for collecting exhaled breath condensate to the Microtox BT Project, and look forward to combining our respective technologies to deliver a real-time solution for the mass surveillance of COVID-19."

 

 

 

For further information please contact:

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

In November 2020, DeepVerge acquired Modern Water who developed and commercialised a cutting-edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.  The Company is in final trials for its real-time contamination product, Microtox PD, for the identification of COVID-19 hotspots and other pathogens.

 

About EcoWaterOS (www.ecowaterOS.com)

Developed by the Rinocloud division of DeepVerge, this is a consortium of partners operating a live dynamic water management system that delivers safe clear water from rivers to wastewater treatment plants using Artificial Intelligence to provide instant alerts from remote sensors direct to stakeholders. It continuously evolves, learns and improves by bringing together multiple existing and smart technologies to create efficient water and deliver environmental protection. Over-the-air monitoring keeps stakeholders constantly up to date with web and mobile alert applications adapted for each group.

 

About PulMoBioMed Limited

PulMoBioMed is spin-out technology company from Northumbria University who have created a non-invasive device designed to collect exhaled breath condensate free from saliva.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCUSURRRBUAAAA

Close

×

RNS Number : 0210F

NetScientific PLC

11 November 2020

 

NetScientific plc

("NetScientific" or the "Company")

 PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

 PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency

London, UK – 11 November 2020 – NetScientific plc (AIM: NSCI), the life sciences, technology investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.

Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021.

 

"PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19," said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology.

 

"PDS Biotech and Farmacore are now one step closer to advancing our Versamune®-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generation vaccine in planned human clinical trials in partnership with Farmacore and to advance our understanding of the potential of novel Versamune®-based vaccines like PDS0203 to provide long-term protection against infection with viruses such as SARS-CoV-2."

 

NetScientific holds approximately 5.75% of PDS' undiluted share capital.

The full details of the announcement are set out below and can be found here: https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/454-iotechandarmacorennouncepdatestooevelopmen20201110

# # #

PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine

 

PDS0203 prioritized for clinical development by PDS Biotech and Farmacore after successful meeting with Brazilian Drug Regulatory Agency

 

FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced progress on its co-development program with Farmacore Biotechnology for a Versamune®-based vaccine aimed at preventing COVID-19 infection.

 

Based on promising and robust preclinical data with PDS0203, and in the interest of rapid development, PDS Biotech and Farmacore have jointly prioritized advancement of PDS0203 to human clinical trials. PDS Biotech had previously announced the parallel development of two Versamune®-based COVID-19 vaccines PDS0203 and PDS0204 each containing different SARS-CoV-2 proteins. The decision to jointly develop PDS0203 was made with the support of the Agência Nacional de Vigilância Sanitária (ANVISA) following a successful pre-investigational new drug meeting on November 06, 2020. ANVISA and Farmacore reviewed the PDS0203 data and agreed on the path forward for official submission of a final data package and the phase 1/2 human clinical trial protocol. Farmacore is in discussions with specific agencies of the government to extend the preclinical funding to cover the upcoming human clinical trial anticipated to begin during the first half of 2021.

 

As previously disclosed, PDS Biotech has generated robust preclinical data demonstrating that PDS0203 elicits a 30-45 fold increase in the induction of highly active and potent virus-specific T-cells within 14 days of treatment compared to the vaccine without Versamune®. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. The vaccine has also demonstrated strong and long-lasting induction of neutralizing antibodies. The PDS0203 subunit vaccine is based on recombinant proteins and does not require the use of inactivated viruses, traditional adjuvants, DNA or RNA to induce robust protective immune responses.

 

"PDS0203 may present strong potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19," said Dr. Greg Conn, Chief Scientific Officer of PDS Biotechnology.

 

"PDS Biotech and Farmacore are now one step closer to advancing our Versamune®-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech. "The preclinical results of PDS0203 demonstrate its potential to induce a robust and broad immune response. We look forward to evaluating our next-generation vaccine in planned human clinical trials in partnership with Farmacore and to advance our understanding of the potential of novel Versamune®-based vaccines like PDS0203 to provide long-term protection against infection with viruses such as SARS-CoV-2."

 

"In this global pandemic, it is incumbent upon the scientific community to be flexible and to ensure we are prioritizing the vaccine with the most clinical potential and that we can progress most quickly," said Helena Faccioli, CEO of Farmacore. "We are excited to continue advancing the partnership with PDS Biotech, and we are thrilled to have the support of ANVISA to provide the opportunity to develop a treatment in Brazil in the fight against this pandemic."

 

The companies plan to utilize multiple research and development sites in the United States and Brazil to progress preclinical and clinical development PDS0203.  Farmacore will lead the regulatory and clinical trial efforts in Brazil while PDS Biotech will continue to contribute scientific expertise and operational support.

 

About PDS Biotechnology

 

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

 

About Farmacore

 

Farmacore is a biotechnology company, founded in 2005 as a startup, focusing on R&D of innovative immunobiological products for use in the human and veterinary health sectors. It is a technology-based company that conducts research and development of biotechnological products and processes for the human and veterinary sectors. It develops innovative biotechnological and immunobiological products and adds value to them in all stages of development, from project design to biomolecule production www.farmacore.com.br.

 

About PDS0203

 

PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed by PDS Biotech and Farmacore. PDS0203 combines the utility of PDS Biotech's Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune® platform, due to its unique ability to induce both antibody and T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19 .

 

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

For more information, please contact:

NetScientific 

Ilian Iliev, CEO  Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel  Tel: +44 (0)20 7220 1666

 

About NetScientific

NetScientific is a life sciences, technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.

For more information, please visit the website at    www.NetScientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RESFLFISLTLLLII

Close

×

RNS Number : 7204E

Solid State PLC

10 November 2020

 

 

RNS Reach – this is a non-regulatory announcement

 

 

10 November 2020

 

Solid State plc

("Solid State", the "Group" or the "Company")

Steatite secures Innovate UK funding to develop a

zero-emission powertrain solution for non-road mobile machinery

 

 

Solid State plc (AIM: SOLI), the AIM listed manufacturer of computing, power and communications products, and value added supplier of electronic and opto-electronic components, is pleased to announce that its Manufacturing division, Steatite, has secured funding from Innovate UK, the UK's innovation agency, for the development of its battery powertrain solution for non-road mobile machinery under its Sustainable Innovation Fund initiative.  The aim of the research and development projects under the fund is to help all sectors of the UK economy build back better over the next two years after the effects of COVID-19. 

 

The Company's Power business unit will develop a modular battery pack with a tailored battery management system which will be combined with a British sourced bespoke electric motor, providing a scalable, modular, zero emission powertrain solution. This powertrain will initially be installed in a woodchipper manufactured by GreenMech Ltd, Europe's leading woodchipper manufacturer, with the aim to be the first UK manufactured zero emission industrial woodchipper. The initial development process is expected to take 3 months.

 

In the longer term, the 100% UK designed and manufactured off-the-shelf powertrain using scalable modular batteries will be available for a multitude of light industrial plant equipment applications.

Matthew Richards, Steatite's Managing Director, commented:

"With the UK government's commitment to achieving a net zero carbon emission economy by 2050, many highly polluting sectors are now falling under the spotlight, such as small plant equipment.

 

"The move from fossil fuels to electric battery power will render these machines carbon neutral, aiding the reduction in pollution, particularly within the urban environment where many of these machines are operated.

 

"Steatite is once again driving world-class British innovation and playing its part in the net zero goal. The Innovate UK involvement has enabled us to accelerate our research and development in this sector supporting British jobs."

 

Innovate UK Executive Chair, Dr Ian Campbell, added:

"In these difficult times we have seen the best of British business innovation. The pandemic is not just a health emergency but one that impacts society and the economy.

 

"Steatite's zero-emission powertrain solution for non-road mobile machinery project, along with every initiative Innovate UK has supported through this fund, is an important step forward in driving sustainable economic development. Each one is also helping to realise the ambitions of hard-working people."

 

 

For further information please contact:

 

Solid State plc	Via Walbrook PR
Gary Marsh – Chief Executive Peter James – Group Finance Director	[email protected]
Walbrook PR (Financial PR)	020 7933 8780
Tom Cooper / Paul Vann	0797 122 1972
	[email protected]

 

 

Analyst Research Reports:   For further analyst information and research see the Solid State plc website: https://solidstateplc.com/research/

 

 

Notes to Editors:

 

Solid State plc (SOLI) is a value added electronics group supplying industrial and military markets with ruggedised/durable components, assemblies and manufactured units for use in harsh environments.  The Group's mantra is – 'Trusted technology for demanding applications'.  To see an introductory video on the Group – https://youtu.be/bp4WfLCEc5Y  

 

Operating through two main divisions: Manufacturing (Steatite) and Value Added Supplies (Solid State Supplies & Pacer); the Group specialises in complex engineering challenges often requiring design-in support and component sourcing for computing, power, communications, electronic and optoelectronic products.

 

Headquartered in Redditch, Solid State employs over 200 staff across the UK with a branch office in the USA, serving specialist markets in oil & gas production, transportation, medical, construction, security, military and field maintenance. 

 

Solid State was established in 1971 and admitted to AIM in June 1996.  The Group has grown organically and by acquisition – having made 10 acquisitions since 2002.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAFLFLELFLAIII

Close

×

Neville Registrars is delighted to welcome Harrogate Group plc as the newest addition to its list of client companies.

Harrogate Group invests in and manages businesses with ethical focus and growth potential with a current focus in youth employment training services.

Further information can be found on the Company's website: https://www.harrogategroupplc.co.uk/

Close

×

RNS Number : 5002D

Character Group PLC

28 October 2020

 

 

 

 

 

The Character Group plc

("Character", or "Group")

Designers, developers, and international distributor of toys, games, and giftware

 

 

TRIO OF TOP TOYS IN THIS YEAR'S DREAMTOYS LISTING FOR CHARACTER GROUP

 

 

LONDON: WEDNESDAY, 28 OCTOBER 2020:   The Board of Character (AIM: symbol: CCT.L) is pleased to announce that its principal trading subsidiary, Character Options Limited   has featured strongly in the prestigious best toys of the year wish list, the official 12 "Dream Toys" 2020 announced by the Toy Retailers Association (TRA) in London today.

 

The DreamToys list is recognised as the most authoritative prediction of toys that will be sought after at Christmas in the UK.  The toys have been selected by an independent, representative panel of UK retailers and industry experts and these toys are expected to be the focus of consumer attention for the coming festive season.

 

THREE of Character's hero toys have been selected in the DreamToys Top 12 toys list for Christmas:

 

Ø Peppa Pig' s Shopping Centre Playset – a multi featured toy for fans of Peppa;

Ø Laser Battle Hunters – the ultimate in remote control vehicles with a unique side winding action; and

Ø Pokémon Carry Case Playset – the first playset for this popular brand.

 

In addition to the 'Dream Dozen', further toys were named as the most sought after in their categories.  Amongst these were FIVE other toys from Character Options' portfolio:

 

Ø Squeakee the Balloon Dog and Gotta' Go Flamingo;

Ø Heroes of Goo Jit Zu Series 2 figures;

Ø PenSilly the family game; and Ø Stuff-a-loons , a fun creative line.

 

Although this year the DreamToys event has had to be held virtually to respect social distancing guidelines, this has not detracted from the prestige and standing within the industry associated with this influential listing .  The virtual presentation of the Dream Toys Top 12 has also seen a larger number of social media platforms sharing the news in real time and to a wider audience.

 

Jerry Healy, Executive Director & Group Marketing Director, commented:

 

"Over the last 10 years since the DreamToys list was established, Character has been represented strongly and this year is no exception.  This event is a high point in our annual marketing calendar as it provides a unique opportunity to obtain an objective assessment of our toy product portfolio and comparisons with the best of the rest.  We are delighted to see three Character products achieving acknowledgement and recognition in what has been an extraordinary year for the industry .   This achievement has been the result of months of work in creating further awareness for the Character toy lines and is also a testament to the effort from our global team and the quality and relevance of our toys ."  

 

 

Full details of the complete 2020 DreamToys list can be found at: https://www.toyretailersassociation.co.uk/dreamtoys-2020 .

 

ENQUIRIES:   The Character Group plc Jon Diver, Joint Managing Director Kiran Shah, Joint Managing Director Jerry Healy, Group Marketing Director

Office:  +44 (0) 208 329 3377 Mobile:  +44 (0) 7831 802219 (JD) Mobile:  +44 (0) 7956 278522 (KS) Mobile:  +44 (0) 7753975421 (JH) Email: [email protected] Websites: www.thecharacter.com www.character-online.com

Panmure Gordon (Nominated Adviser and Joint Broker) Atholl Tweedie, Investment Banking Charles Leigh-Pemberton , Corporate Broking Tel:  +44 (0) 20 7886 2500

Allenby Capital Limited (Joint Broker) Nick Athanas, Corporate Finance Amrit Nahal, Sales & Corporate Broking Tel:  +44 (0) 20 3328 5656

TooleyStreet Communications Limited (investor and media relations) Fiona Tooley Tel:  +44 (0) 7785 703523 Email: [email protected]

Evolution PR (Trade and consumer media) Michele Bates Tel: +44 (0) 01327 227010 Email: [email protected]

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAUWVARRRURUAA

Close

×

RNS Number : 6986C

LoopUp Group PLC

21 October 2020

 

21 October 2020

 

LOOPUP GROUP PLC
(the "Group")

Launch of LoopUp Rooms

Simple, accessible and competitively-priced HD video conferencing suites

 

LoopUp Group plc (AIM: LOOP), the premium cloud communications provider, is pleased to announce the launch of LoopUp Rooms. LoopUp Rooms combines the Group's premium remote meeting solution with off-the-shelf hardware to create competitively-priced, plug-and-play video conferencing suites accessible to all users.

 

As businesses see an increase in remote and hybrid working, demand is growing for collaborative spaces that allow employees to communicate securely and productively with clients and colleagues. Until recently, video suites have often been expensive to install, complex to use and inaccessible to many employees. By contrast, LoopUp Rooms is a simple, plug-and-play solution that can be set up in minutes and uses off-the-shelf hardware – a display screen, a high quality camera, a mini-PC, a touch-screen controller and a conference room phone.

 

Users join meetings with one touch from a touch-screen controller, which then uses the high quality video and display of the room's screen and camera, and reliable managed quality-of-service audio of the room's speaker phone. Users can reserve the meeting room direct from Outlook, which adds their LoopUp meeting details to the calendar on the room's touch-screen controller for easy joining.

 

Steve Flavell and Michael Hughes, co-CEOs of LoopUp Group, commented,

"With remote and distributed working now the new normal for many, a growing number of meetings are taking place by video conference. Businesses need more meeting rooms equipped with technology for employees to collaborate effectively and comfortably with clients and colleagues. We're facilitating this by making premium video conferencing suites more cost competitive, accessible and intuitive for users without having to call upon IT for assistance."

 

 

For further information, please contact:

LoopUp Group plc	via FTI
Steve Flavell, co-CEO
Panmure Gordon (UK) Limited	+44 (0) 20 7886 2500
Dominic Morley / Alina Vaskina (Corporate Finance)
Erik Anderson (Corporate Broking)
Numis Securities Limited	+44 (0) 20 7260 1000
Simon Willis / Jonny Abbott (Corporate Finance)
FTI Consulting, LLP	+44 (0) 20 3727 1000
Matt Dixon / Emma Hall / Jamille Smith / Shamma Kelly

 

About LoopUp Group plc:

LoopUp (LSE AIM: LOOP) is a global platform for business-critical external cloud communications, which combines premium capabilities for cloud telephony, remote meetings and managed events. Our customers benefit from a fully-managed service, globally, and an emphasis on security, reliability and simplicity, delivered with deep domain expertise and caring customer support. We're proud to be trusted provider to over 5,000 organisations worldwide, including more than 20 of both the world's top-100 law firms and top-100 private equity firms, as well as enterprises such as Travelex, Kia Motors, Planet Hollywood and National Geographic. The Group is headquartered in London, with offices in San Francisco, New York, Boston, Chicago, Dallas, Los Angeles, Denver, Cardiff, Milton Keynes, Madrid, Berlin, Malmo, Hong Kong, Sydney and Barbados, and is listed on the AIM market of the London Stock Exchange (LOOP). For further information, please visit: www.loopup.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCPPGUGUUPUGQU

Close

×

RNS Number : 3973C

Midatech Pharma PLC

19 October 2020

 

19 October 2020

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Headline Results of MTX110 Phase I DIPG Study

 

Phase II Dose Confirmed and Encouraging Survival Data

 

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce encouraging headline results from a Phase I study at the University of California, San Francisco ("UCSF") in patients with Diffuse Intrinsic Pontine Glioma ("DIPG") (the "UCSF study" NCT03566199).

 

The primary endpoint of the study was to determine the dosage regimen to be used in a proposed Phase II study of the safety and efficacy of MTX110 in patients with DIPG.  Preliminary high-level data from the UCSF study supports a dose of between 60μM and 90μM of MTX110, depending upon patient tolerance over the course of 12 infusions in Phase II.  

 

In total, seven patients were recruited into the UCSF study. Patients were newly diagnosed with DIPG and received focal external beam radiation therapy four to 14 weeks before commencement of MTX110 treatment.  Eligibility required a pontine location of the tumour with diffuse involvement of at least two thirds of the pons and no evidence of metastatic disease.  Patients were not excluded by total tumour volume. MTX110 was administered directly into the tumour via a micro-catheter using convection enhanced delivery ("CED") with gadolinium-enhanced intra-operative MRI to guide and track drug distribution to the tumour.  Patients could receive up to 12 cycles of treatment every four to eight weeks.  The dose was escalated between and within patients as tolerated initially by increasing the infusion volume at a concentration of 30μM MTX110 and then with higher drug concentrations of 60μM and 90μM as the sixth and seventh dose increments, respectively.

 

At the interim cut-off date (30 September 2020), median overall survival based on Kaplan Meier analysis was 26.06 months (CI 11.3 – 26.06 months) and overall survival at 12 months (OS12) was 71.4% (five of seven patients alive).  Three patients remain alive and continue to be monitored.  Survival was not an endpoint of the UCSF study nor was the study powered for statistical significance and therefore no conclusions as to the impact of MTX110 on overall survival rates can be drawn from these data.

 

The proposed Phase II trial is expected to evaluate overall survival at 12 months as the primary endpoint in 19 evaluable patients.  The planned design is single arm and statistically powered for comparisons with defined historical survival data.  MTX110 is expected to be delivered using an alternative CED catheter system that enables regular drug infusions directly into the tumour without a need for repeated surgery.

 

DIPG is a primary brain tumour arising in the pons (middle) of the brain stem, is diffusely infiltrating and cannot be surgically removed. Occurring mostly in children, the median survival rate in a cohort of 316 cases was 10.0 months and OS12 was 35% (Jansen et al, 2015. Neuro-Oncology 17(1):160-166). Although radiotherapy prolongs survival, the majority of patients die within one year following diagnosis. Systemic chemotherapy is ineffective, often due to an inability of agents to cross the blood-brain barrier. Approximately 1,000 (data on file) individuals are diagnosed with DIPG worldwide each year.

 

Commenting Sabine Mueller MD PhD, Principal Investigator of the UCSF study, said: "The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.  In an upcoming Phase II study efficacy in this patient population will be assessed."

 

Commenting further, Steve Damment, EVP R&D of Midatech, said: "DIPG is a devastating pediatric brain cancer with limited treatment options and very poor outcomes.  The overall survival data from this Phase I study are encouraging, although further study of MTX110 in DIPG is required to establish whether it can make a difference to these patients and their families."

 

Online Q&A Session

 

Stephen Stamp (CEO and CFO) and Steve Damment (EVP R&D) will be hosting an online Q&A session regarding this latest development at 2.00 p.m. London time / 9.00 a.m. US East Coast time on Monday 19 October 2020.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via:

https://us02web.zoom.us/webinar/register/WN_fwS5OEm8QiG5Uz7JvjWQ-A where they will be provided with access details.  Participants will have the opportunity to ask questions during the session, but questions may also be submitted in advance to : [email protected] 

 

About MTX110

MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations.  Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27).  MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559). 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Midatech Pharma PLC

Stephen Stamp, CEO, CFO Steve Damment, EVP R&D

Tel: +44 (0)29 20480 180

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker (Corporate Broking) Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: [email protected]

Edison Group (US Investor Relations) Megan Paul Tel: +1 (646) 653 7034 Email: [email protected]

 

About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.   The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:   · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.   The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

 

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCFIFFAIRLDLII

Close

×

RNS Number : 1298C

Osirium Technologies PLC

15 October 2020

 

15 October 2020

RNS REACH

 

 

Osirium Technologies plc

("Osirium" or "the Group")

 

Competitive contract win for PAM and PEM solutions with leading healthcare provider

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a leading provider of health services across the UK. The order was secured against competition from two other suppliers of Privileged Access Management ("PAM") technologies.

 

The new customer has made a multi-product purchase including Osirium's PAM solution and 5,000 endpoints of Osirium's Privileged Endpoint Management ("PEM") platform. This combination provides them a complete solution from protecting privileged user accounts through to protecting privileges at the end-point level. Osirium's Professional Services team will assist with the implementation and rollout of both products as part of the contract. 

 

Key factors in both Osirium PAM and Osirium PEM being selected over competitors were Osirium's collaborative and consultative engagement model and approach to the project. The solutions' simplicity of deployment and ease of use were also large factors in the decision as the customer is looking to deploy rapidly to gain an immediate return on investment. The transparency of the licensing model made it straightforward to see what was included in Osirium's offering, and the ability of Osirium's PAM platform to securely automate essential processes was also a key differentiator.

 

The Osirium solutions are to be implemented to address multiple operational and security challenges. Addressing potential threats to the IT infrastructure, such as ransomware attacks, Osirium PEM will control and remove local user admin rights, while the PAM platform will be used to control and audit internal and third party access to critical servers, applications and networking equipment, including the ability to automate simple and complex IT tasks.

 

David Guyatt, Chief Executive Officer, commented: "Having finished the previous quarter with a string of excellent orders from new clients, I am delighted that Osirium is starting the new quarter in a similar vein with another new customer and competitive win.

 

Our industry regularly talks about the 'Principle of Least Privilege' – delivering security by permitting only the minimum level of privileged access. By offering the complete Privileged Access Security portfolio of solutions, we help customers make this principle a reality, and this new contact win is a clear illustration of that philosophy. Osirium PAM secures the vital infrastructure and Osirium PEM provides the balance between infrastructure and users, making the desktop safer than ever."

 

 

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Richard Short
Alma (Financial PR) David Ison / Josh Royston / Kieran Breheny	Tel: +44 (0) 203 405 0205

 

Notes to Editors:

 

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRADZLFFBBLXFBL

Close